To date several algorithms for longitudinal analysis of ovarian cancer biomarkers have been proposed in the literature. An issue of specific interest is to determine whether the baseline level of a biomarker changes significantly at some time instant (change-point) prior to the clinical diagnosis of cancer. Such change-points in the serum biomarker Cancer Antigen 125 (CA125) time series data have been used in ovarian cancer screening, resulting in earlier detection with a sensitivity of 85% in the most recent trial, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, number ISRCTN22488978; NCT00058032). Here we propose to apply a hierarchical Bayesian change-point model to jointly study the features of time series from multiple biomarkers. For this model we have analytically derived the conditional probability distribution of every unknown parameter, thus enabling the design of efficient Markov chain Monte Carlo methods for their estimation. We have applied these methods to the estimation of change-points in time series data of multiple biomarkers, including CA125 and others, using data from a nested case-control study of women diagnosed with ovarian cancer in UKCTOCS. In this way we assess 1/21 whether any of these additional biomarkers can play a role in change-point detection and, therefore, aid in the diagnosis of the disease in patients for whom the CA125 time series does not display a change-point.
the statistical inference technique for the longitudinal analysis of ovarian cancer biomarkers developed by 10 Skates et al. [5] [6] [7] , where the main assumption is the existence of a change-point in the serum CA125 11 time series as the tumour develops. In particular, the level of CA125 is assumed to remain approximately 12 constant until, at some time instant, it begins to increase significantly. The latter time point is referred to 13 as a change-point. The algorithm proposed in [5] is based on a hierarchical Bayesian model that includes 14 the change-point as one of the random parameters to be estimated. 15 In this paper, we jointly analyse time series data from multiple biomarkers to determine whether the 16 level of these markers changes significantly and coherently at specific time instants. The detection of 17 such a change-point may contribute to the earlier diagnosis of the disease. Although the serum CA125 18 is the most useful biomarker in the screening of ovarian cancer, multiple serum biomarkers have been 19 reported to be associated with the development of ovarian cancer and to possibly improve the performance 20 of CA125 when used in combination [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The biomarker that has received more attention is the 21 Human Epididymis Protein 4 (HE4), which has been used in the ROMA (Risk of Ovarian Malignancy 22 Algorithm) to discriminate ovarian cancer from benign diseases [8, 18] as well as in different panels for the 23 purpose of early detection [9] [10] [11] . In a study within the Prostate Lung Colorectal and Ovarian (PLCO) 24 cancer screening trial [19] , HE4 was the second best marker after CA125 with a sensitivity of 73% (95% 25 confidence interval 0.60 -0.86) compared to 86% (95% confidence interval 0.76 -0.97) for CA125 [12, 20] . 26 Another serum biomarker glycodelin has also shown promising performance in the detection of ovarian 27 cancer [13, 14, 21] . Other markers that appear to be promising when used in multi-marker panels include 28 matrix metalloproteinase-7 (MMP7) [13, 20, 22] , cytokeratin 19 fragment (CYFRA 21-1) [15, 20] and 29 mesothelin (MSLN) [11, 16] . 30 In order to incorporate this information we assume a hierarchical Bayesian change-point model for 31 different biomarkers in addition to serum CA125. Statistical inference in this model can be carried out 32 using Markov chain Monte Carlo (MCMC) methods [23] . In particular, we have analytically obtained 33 the full conditional probability distributions for all the unknown parameters in the model, thus enabling 34 the design of an efficient Metropolis-within-Gibbs algorithm [24] for their Bayesian estimation. We apply 35 this technique to the estimation of change-points in time series data, including CA125 and the other 36 biomarkers in patients diagnosed with ovarian cancer and in a control group of healthy individuals. We 37 assess whether any of these additional biomarkers can play a role in ovarian cancer diagnosis by either 38 detecting a change-point in any of the available biomarkers earlier than in CA125 or by detecting a 39 change-point in women in whom the CA125 does not display a change-point. We also investigate whether 40 the change-points for different biomarkers occur at similar time points.
41
The Bayesian estimation approach advocated in this paper aims at producing a full statistical 42 characterisation of the unknown model parameters, given in the form of their posterior probability 43 distribution conditional on the available data. The proposed Metropolis-within-Gibbs algorithm yields a 44
Monte Carlo approximation of this posterior distribution, which enables the implementation of a variety 45 of estimators for the parameters and provides the means to evaluate their accuracy and reliability as well. 46 While in this paper we keep the change-point estimation process relatively simple, the framework and 47 algorithms described in Sections 2 and 3 lends itself to potentially advantageous extensions.
48
The rest of this paper is organised as follows. Section 2 is devoted to the description of the dataset 49 and the hierarchical Bayesian model used to represent it. The inference algorithm for the detection and 50 estimation of change-points in biomarker time series is introduced in Section 3. The results obtained for 51 the available dataset are shown and discussed in Section 4. Section 5 is devoted to the conclusions. 
Dataset

54
In this study we have used a dataset from the multimodal arm of the UK Collaborative Trial of Ovarian 55
Cancer Screening (UKCTOCS) [25] , where women underwent annual screening using the blood tumour 56 marker CA125. HE4, MMP7, CYFRA 21-1, Glycodelin and MSLN assays were performed on stored 57 serial samples from a subset of women in the multimodal arm diagnosed with ovarian cancer. average age over all the subjects and samples is 63.6 years. The range of ages for the diagnosed patients 66 (cases) is 52-77.4 years and the average age over all patients and samples is 65.5 years.
67
It should be noted here that all the biomarker measurements have been modified via a logarithmic 68 transformation, as detailed in [5, 14] , in the form of Y = log(Z + 4), where Z is the value of a particular 69 marker. For most patients with ovarian cancer prior to disease diagnosis, serum CA125 rises exponentially. 70 This transformation allows us to observe a linear change in time. Let Y ij denote the log-transformed measurement of the biomarker Z (where Z can be any of CA125, 74 HE4, Glycodelin, MSLN, MMP7 or CYFRA 21-1) for the i-th patient in the study at age t ij , where 75 j = 1, . . . , k i represents the ordinal of the observation for patient i (i.e., the first observation, the second 76 observation, and so on), being k i the total number of measurements for patient i. The values of the 77 biomarkers are collected at time points t ij , which can depend on previous values Y ij , j < j. For this 78 model, an unobserved binary indicator I i is included to distinguish subjects whose ovarian cancer does 79 (I i = 1), or does not (I i = 0), produce an increased biomarker level. Notice that for patients with I i = 0 80
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there is no way to tell them from healthy individuals by looking at that biomarker alone. Within the 81 proposed hierarchical model, separation of cases that do not produce a change-point from those that 82 do produce it enables a more precise estimation of individual change-points and rates of change. The 83 indicator I i for each case is assumed to follow, a priori, a Bernoulli distribution with success probability 84 π, where π represents the proportion of cases that produce an increased biomarker level. As in [5] , in 85 light of the observation of Kabawat et al. [27] that approximately 15% of ovarian cancer cases do not 86 produce an excess of biomarker CA125, a Beta(42.5,7.5) prior distribution with mean 0.85 and standard 87 deviation 0.05 is adopted as the prior distribution of π. We assume the same prior distribution of π for all 88 the biomarkers studied in this paper. 1 The selection of proper priors is important. Under improper priors, such as the Jeffrey's priors utilised in [5] , it becomes necessary to verify whether the posterior distributions are proper or not. If they are not, any computational inference methods applied to approximate the posterior distributions may become numerically unstable and yield unreliable estimates of the quantities of interest.
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priors as in [5] for µ θ and σ θ , that is, µ θ ∼ N (2.75, 1) and σ 2 θ ∼ IG(2.04, 0.065).
100
When the binary indicator is I i = 1, the log-transformed biomarker level starts increasing at a 101 positive rate γ i after the unobserved time instant τ i , which is modelled as random and referred to as the 102 change-point of the time series. As a consequence, the mean of the biomarker level is represented by way 103 of the piecewise linear function
where (·) + denotes the positive part of the expression between brackets and θ i is random and modelled 105
in the same way as described above. A normal distribution with constant variance σ 2 is again specified 106
to model variations around the expected level. Thus, the marker level is conditionally distributed as 107
, where the prior for σ 2 has been chosen the same as before, i.e., 108 years has been estimated from the ratio of prevalence to incidence in a series of screening trials [28] [29] [30] 
Metropolis-within-Gibbs sampling
118
We propose to compute Bayesian estimates of the unknown parameters in the model using a Gibbs 119 sampling scheme [23] . To implement this kind of method, it is necessary to obtain the full conditional 120
distributions of all the parameters in the model. These distributions have been explicitly derived and are 121
given in Appendix A, together with the joint density of all the parameters and the observed data, being one 122 of the contributions of this work. Notice that the conditional distributions of τ i and log γ i are not standard 123 and therefore it is not possible to draw samples from them directly. To circumvent this difficulty, we run 124
several steps of a Metropolis-Hastings (MH) algorithm for each one of the parameters τ i and log γ i (and 125
for each patient i) at each iteration of the Gibbs sampler (see Section 3.1). The resulting sampling scheme 126
is often termed Metropolis-within-Gibbs (MwG) [24] or Component-wise Metropolis-Hastings [31] [32] [33] . The 127 need to generate a relatively long chain of samples in the embedded MH algorithms has been discussed in 128 the literature [41] [42] [43] . In this paper, we generate a chain of 200 samples for each of the variables τ i and 129
log γ i at each iteration of the MwG algorithm.
130
The proposed MwG algorithm iteratively generates samples from the distribution of each parameter 131 conditional on the current values of the other parameters. It can be shown that the resulting sequence of 132 samples yields a Markov chain, and the stationary distribution of that Markov chain is the joint posterior 133 probability distribution [24] .
134
In order to describe the proposed MwG sampling algorithm let us introduce the sets
that contains the model parameters which are common to all subjects, and
contains the parameters which are specific to the i-th subject. If we study a dataset including series 137 from m subjects, then the complete set of parameters is A = m i=1 S i C, that contains n = 6 + 4m 138 parameters to be estimated. Besides, we use the shorthand x ∼ M H G (σ that produces a Markov chain of J elements with initial condition x 0 . In our case, x may refer to τ i or 141 log γ i . Complete details are given in Appendix B.
142
We use an argument-wise notation for probability density functions (pdf's) and probability mass 143 functions (pmf's). If x and y are two continuous random variables (r.v.), then p(x) and p(y) denote the 144 pdf's of x and y, respectively. These pdf's are possibly different. Similarly, p(x, y) denotes the joint pdf of 145
x and y and p(x|y) is the conditional pd of x given y. The same notation is used for pmf's, e.g., if z is a 146 discrete r.v. then p(z) is its pmf. In our model the only discrete r.v.'s are the indicators I i , i = 1, . . . , m. 147
The proposed MwG algorithm can now be outlined as follows.
148
Initialisation. For each parameter in C, draw an initial sample from its a priori pdf, i.e., draw µ sample from the corresponding prior pdf/pmf, i.e., draw θ
Iteration. For k = 1, 2, . . . , K;
154
• Draw new samples for the common parameters
where Y denotes the full dataset. These conditional pdf's are given explicitly in Appendix A.
156
• Draw new samples from the subject specific parameters:
The conditional pdf's for θ i , I i ,τ i and log γ i are given explicitly in Appendix A as well. Running 158 the MH algorithm to generate the new samples τ remaining parameters generated at the k-th iteration. Other alternatives for the efficient implementation 160
of Gibbs-based samplers have been explored in the literature [34] [35] [36] [37] [38] [39] [40] and can also be applied within the 161 proposed framework. 
Change-point detection
163
The MwG algorithm is run to generate a Markov chain of K = 10000 samples for each unknown parameter 164 in the set A. We allow a burn-in period [23] of L = 5000 samples, which are discarded. The remaining 165 K − L = 5000 samples in the Markov chain can be used for estimation.
166
The estimate of the probability p(I i = 1|Y ) is used to detect the presence of a change-point in the time 167
series of patient i. We can estimate p(
we detect a change-point for the time series of the i-th subject. We can estimate the position (time 169 instant) of this change-point
i . Note that this estimate is only meaningful when 170
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p(I i = 1|Y ) > 0.5. We may computeτ i whenp(I i = 1|Y ) < 0.5 as well, but in this case we do not detect 171 a change-point so this value ofτ i is not relevant.
172
It is also of interest to determine whether the change-points for different biomarkers obtained from 173 the same patient can be expected, a priori, to occur at similar time instants. (Note that biomarker 174 change-points are not guaranteed to exist for all biomarkers in all patients). We have analysed the available 175 data in terms of the interval between measurements where the change-point is detected for the different 176 biomarkers and patients in the dataset.
177
Let t i,0 , . . . , t i,ki be the times at which measurements are collected for patient i. For a given biomarker, 178 we say that the change-point is detected at interval 0 when our estimateτ i is less than t i,0 ; we say that 179 the change-point is detected at interval 1 when our estimateτ i is between t i,0 and t i,1 , etc.. In general, a 180 change-point for subject i is detected at the j − th interval whenp(I i = 1|Y ) > 0.5 and t i(j−1) ≤τ i < t ij , 181 for j = 1, . . . , k i . Thus, with k i measurements, the change-point for the given biomarker can be detected 182 within k i different time slots, labeled 0, 1, 2, . . . , k i − 1.
183
Once the change-points for the available biomarkers have been assigned a time slot each, it is possible to 184 compare them in pairs and see whether the change-points occur in the same slot or whether one biomarker 185 precedes the other. As this comparison is carried out for all patients and for each pair of biomarkers, 186 it is possible to estimate the probability of coincidences (i.e., how likely it is that change-points of two 187 biomarkers are detected in the same slot) as well as the probability of the change-point of one biomarker 188 being detected in an earlier slot (e.g., slot 1 for the first biomarker versus slot 2 for the second biomarker). 189 These summary statistics are easy to compute, robust to change-point estimation errors and provide useful 190 information to assess the diagnosis. Our numerical results are presented and discussed in the following 191 section.
4 Results and Discussion
193
We have first studied the outcome of applying the proposed method for change-point detection to a control 194 dataset containing time series of 179 healthy subjects and the 6 biomarkers of interest. Each series consists 195 of 4 or 5 sequential samples available for each biomarker. As expected, the probability that a change-point 196 occurs for the control group is small, less than 2.5% for all biomarkers, as shown in Table 1 ).
197
Next we discuss the results for the dataset of patients with ovarian cancer described in Section 2.1. 198 biomarkers can improve detection. Table 2 shows the probability that a change-point occurs (at any time 202 slot) for the different biomarkers. We can see that for CA125, HE4 and Glycodelin the probability is 203 relatively high (more than 84%) whereas for MSLN, MMP7 and CYFRA 21-1 this probability is quite 204 low, specially for the last (20%). This suggests that while the latter biomarkers do not provide significant 205 information for cancer detection, the former could play a significant role. We therefore focus on the first 206 three biomarkers, namely CA125, HE4 and Glycodelin in the rest of our study. A change-point was not detected with CA125 in 11% of patients (and we refer to these cases as false 208 negatives). Therefore HE4 and/or Glycodelin data was analysed to determine whether they could be used 209 to improve detection. We detected a change-point in the HE4 data in 80% of the CA125 false negatives 210
and in the Glycodelin data in 60% of the CA125 false negatives. This suggests that use of two biomarkers 211
together, CA125 plus HE4 or CA125 plus Glycodelin, instead of CA125 alone, can reduce the number of 212 false negatives from 11% to 2% or 4%, respectively.
213
We then analysed the data from women for whom a change-point was observed in CA125 to determine 214 
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whether the HE4 and/or Glycodelin data also showed a change-point and, if so, whether there was 215 coincidence and precedence of the change-points in the same interval of time. obtained with the CA125, HE4 and Glycodelin data, respectively, for every woman. To be specific, 225
Glycodelin be the change-point estimates, measured in years, obtained from the 226 corresponding time series data for the i-th patient (and, as there are 44 individuals in the dataset, 227 i = 1, 2, . . . , 44). Fig. 2 shows the histograms for the differences between all three possible pairs of 228 estimates:
229
• plot (a) displays the histogram for the CA125-HE4 differences, i.e.,τ
HE4 ;
230
• plot (b) displays the histogram for the CA125-Glycodelin differences, i.e.,τ
Glycodelin ; and 231
• plot (c) displays the histogram for the HE4-Glycodelin differences, i.e.,τ
Glycodelin .
232
Note that these differences can only be computed for those patients for whom a change-point has been 233 detected for the two biomarkers in the pair (e.g., the histogram in Fig. 2(a) includes the time differences 234 for individuals for whom a change-point was detected both in the CA125 data and in the HE4 data). 235 We can observe that all histograms are approximately centered around zero, since all biomarkers tend 236 to estimate the change-point in the same time interval with high probability, but a closer look actually 237
shows that the histograms of Figs. 2 (a)-(b) are slightly shifted to the right, which is consistent with with 238 11/21 the observation in Table 3 that, when there is no coincidence in the same time slot, the change-points 239 detected in the HE4 and Glycodelin data appear earlier than the change-point detected in CA125 data 240 with high probability. 
Conclusions
242
We have designed a Bayesian change-point (BCP) model, based on the approach of Skates et al. [5] , that 243 may be used in the analysis of biomarker time-series data, as an aid to the diagnosis of ovarian cancer. It 244 is known that, in approximately 85% of women who go on to be diagnosed with ovarian cancer, CA125 245 data display a change-point (turning from stationary to a linearly increasing trend in the transformed 246 measurements) prior to diagnosis. The detection of such change-points has been used to diagnose the 247 disease earlier. The contribution of this paper is twofold:
248
• For the proposed BCP model we have explicitly computed the conditional probability distributions 249 of all the model parameters. The availability of the conditional probability distribution of all model 250 parameters may have wide theoretical and practical advantages. In particular, it enables the design 251 of efficient and stable computational estimation algorithms for these parameters and, specially, for 252 the change-points.
253
• In a real time-series dataset of samples preceding diagnosis of ovarian cancer, we have applied the 254 proposed BCP model and a Gibbs-sampling based estimation algorithm to detect and estimate 255 change-points in the tumour markers CA125, HE4, MMP7, CYFRA 21-1, MSLN and Glycodelin. In 256 12/21 this dataset, diagnosis based on CA125 alone yields ≈ 11% false negatives, i.e., diagnosed patients 257 for whom the CA125 data does not display a change-point. We have shown that by jointly analysing 258 the CA125 and Glycodelin data, the rate of false negatives is reduced to 4%, while the analysis of 259 CA125 together with HE4 further reduces this rate to a mere 2%.
260
Our results suggest that the change-point approach with combined assay of HE4 or Glycodelin along with 261 CA125 can lead to an earlier diagnosis compared to an approach based on CA125 alone. In particular, we 262 found that for those patients for whom change-points are detected both with CA125 and HE4/Glycodelin, 263 the change-point occurs earlier in the HE4/Glycodelin data in a significant proportion of cases.
264
The proposed Bayesian detection and estimation scheme admits several extensions that can be 265 implemented with limited additional computations. In particular, given the approximate posterior 266 distribution produced by the MwG sampler, it is possible to assess the credibility of the detected change-267 points as well as the accuracy of the estimated times where the change takes place. This capability may 268 lead to further improvements in the reliability of the change-point detection scheme. the parameters which are specific to the i-th subject and m represents the number of subjects. Notice 274 that 6 + 4m is the number of parameters to be estimated.
275
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The full conditional distributions for the common parameters are:
where 
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The full conditional distributions for the model parameters which are specific to each subject are
where
where i represents the subject,m i andv patients). Then, the joint pdf can be written as
where p(Y |A) is the likelihood function and p(A) is the joint prior pdf of the parameters. The latter is 296
readily deduced from the model structure, namely 
where p(σ 2 ) = IG(2.05, 0.1), p(µ θ ) = N (2.75, 1), p(σ (
The joint pdf is obtained by substituting (8) and (9) back into (7) . The resulting function is proportional 304
to the full conditional of a given model parameter if we assign a fixed value to all other parameters.
305
B Appendix: Metropolis-Hastings algorithm
306
The Metropolis-Hastings algorithm can be used to draw samples from any pdf p(x), provided the value 307 of a function f (x) ∝ p(x) can be computed. It works by generating a Markov chain which has p(x) as 308 a stationary (limiting) distribution [23] . The sample x t+1 in the chain is produced using a proposal 309 conditional pdf g(x t+1 |x t ) followed by a random acceptance test. The Metropolis algorithm is a special 310 case of the Metropolis-Hastings algorithm where the proposal function is symmetric and it can be outlined 311 as follows.
312
Initialisation Choose an arbitrary point x 0 to be the first sample, and choose an arbitrary symmetric 313
proposal pdf g(x|y) (g(x|y) = g(y|x)). In this work we have considered a Gaussian distribution centered 314 at y.
315
Iteration. For t = 1, 2, . . .:
316
• Draw a candidate x from the proposal pdf g(x |x t−1 ).
317
• Compute the acceptance ratio α = f (x )/f (x t−1 ).
318
• Draw a uniform sample u ∼ U (0, 1). If u < α then accept x and set x t = x . Otherwise, set 319
x t = x t−1 .
In particular, in our work for each iteration in the Gibbs sampler (see 
